Research & Publications
Epigenetic aberrations often lead to cancer and other human diseases. The long-term goal of our laboratory is to elucidate the roles of epigenetic regulation in cancer and to translate our findings to the clinic. In particular, we focus on the epigenetic regulators of cancer metastasis, tumor immunoevasion and resistance to anticancer drugs. Among these epigenetic regulators, the KDM5/JARID1 histone demethylases are demethylases for tri- methylated lysine 4 in histone H3 (H3K4me3), the epigenetic mark for transcriptionally active chromatin. Using KDM5A/B knockout mouse models, we showed that loss of KDM5A or KDM5B inhibits tumorigenesis in several genetically engineered mouse models. We are currently studying how KDM5 demethylases and other epigenetic regulators contribute to cancer initiation and progression using biochemical, molecular biological, cell biological and mouse genetic approaches. As these epigenetic regulators are potential drug targets, we are developing inhibitors against these regulators for cancer treatment.
Specialized Terms: Epigenetics; Gene regulation; Cancer biology
Breast Neoplasms; Gene Expression Regulation; Immunotherapy; Melanoma; Neoplasm Metastasis; Retroelements; Drug Resistance, Neoplasm; Jumonji Domain-Containing Histone Demethylases; Epigenomics; Epigenetic Repression